ORCA Therapeutics B.V. is excited to announce that it has successfully secured $2 million in funding to accelerate the development of its innovative oncolytic immunotherapy platform. As a privately-funded biopharmaceutical company, ORCA is at the forefront of revolutionizing cancer treatment through its unique design of Oncolytic Replication Competent Agents (ORCA). These engineered oncolytic adenoviruses are specifically formulated to target and selectively kill cancer cells, stimulating a robust antitumor immune response in patients. The recent round of financing will primarily support the advancement of ORCA’s lead compound, ORCA-010, which is being developed for treatment-naive patients suffering from prostate cancer. This pivotal funding will enable ORCA to further its research and clinical trials, laying the groundwork for potentially life-saving therapies that harness the power of viruses to combat cancer. The investment signifies strong investor confidence in ORCA’s cutting-edge approach and the promise of oncolytic immunotherapies in the fight against cancer. As we move forward, ORCA remains firmly committed to its mission of using science and innovation to transform the landscape of cancer treatment, aiming for breakthroughs that can extend life and improve quality of life for patients globally. For more information about ORCA Therapeutics and our groundbreaking research, please visit our website at http://www.orca-therapeutics.com.
ORCA Therapeutics Secures $2 Million in Funding to Revolutionize Cancer Treatment with Oncolytic Immunotherapies
Recently funded · €2.0MHealthcare
Get the full ORCA Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
